Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.62 |
| ▸ | GSR | P00390 | 2/20 | 0.56 |
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696195 | 1.00 | SLC1A2 (0.62) | SLC1A2GSRARG2ARG1NOS2 | |
| SCHEMBL25662044 | 0.93 | SLC1A2 (0.60) | SLC1A2GSRARG2ARG1NOS2 | |
| SCHEMBL8126946 | 0.93 | SLC1A2 (0.60) | SLC1A2GSRARG2ARG1NOS2 | |
| SCHEMBL8530336 | 0.93 | SLC1A2 (0.60) | SLC1A2GSRARG2ARG1NOS2 | |
| SCHEMBL25660492 | 0.91 | SLC1A2 (0.58) | SLC1A2GSRARG2ARG1NOS2 | |
| SCHEMBL30562964 | 0.88 | — | — | |
| SCHEMBL21411550 | 0.88 | — | — | |
| SCHEMBL2708260 | 0.88 | — | — | |
| SCHEMBL158491 | 0.88 | — | — | |
| SCHEMBL13318957 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339315-B1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | RETROTOPE INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-10918126-B2 | Isotopically modified compounds and their use as food supplements | RETROTOPE, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10918126-B2 | Isotopically modified compounds and their use as food supplements | RETROTOPE, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180303145-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | BIOJIVA LLC | 2018-10-25 | — | — | US | disclosed |
| US-10015979-B2 | Isotopically modified compounds and their use as food supplements | RETROTOPE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10015979-B2 | Isotopically modified compounds and their use as food supplements | RETROTOPE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3339315-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | Retrotope, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339315-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | Retrotope, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170172195-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | BIOJIVA LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170172195-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | BIOJIVA LLC | 2017-06-22 | — | — | US | disclosed |
| US-20150147457-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | BIOJIVA LLC | 2015-05-28 | — | — | US | disclosed |
| US-8906405-B2 | Isotopically modified compounds and their use as food supplements | RETROTOPE, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20100160248-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | BIOJIVA LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160248-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | BIOJIVA LLC | 2010-06-24 | — | — | US | disclosed |
| EP-1991068-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | Shchepinov, Mikhail Sergeevich (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007102030-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | SHCHEPINOV MIKHAIL SERGEEVICH (GB) | 2007-09-13 | — | — | WO | disclosed |
| US-6313097-B1 | TREATMENT OR PROPHYLAXIS OF MIGRAINE OR CLUSTER HEADACHES, NON-INSULIN-DEPENDENT DIABETES MELLITUS, INFLAMMATION, ALLERGIC RHINITIS, ASTHMA, MORPHINE TOLERANCE, MENOPAUSAL HOT FLASHES, DISEASES CHARACTERIZED BY EXCESSIVE VASODILATATION | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-06 | — | — | US | disclosed |
| US-6114390-A | AN ARGININAMIDE OR ORNITHINAMIDE COMPOUND AS TREATING MEMORY LOSS, MIGRAINE, SLEEP DISORDERS, PAIN, CARDIOVASCULAR DISEASES, SUBARACHNOIDAL BLEEDING, VASCULAR-HYPERTROPHIC CHANGES, CEREBRAL AND CORONARY VASOSPASMS | KARL THOMAE GMBH (DE) | 2000-09-05 | — | — | US | disclosed |
| EP-0885186-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172195-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | GPX4, FABP6, SLC25A20 | SLC1A2 243/4885GSR 206/4885ARG2 318/4885 |
| US-10015979-B2 | Isotopically modified compounds and their use as food supplements | GPX4, FABP6, SLC25A20 | SLC1A2 243/4885GSR 206/4885ARG2 318/4885 |
| US-20180303145-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | GPX4, FABP6, SLC25A20 | SLC1A2 243/4885GSR 206/4885ARG2 318/4885 |
| US-10918126-B2 | Isotopically modified compounds and their use as food supplements | GPX4, FABP6, SLC25A20 | SLC1A2 243/4885GSR 206/4885ARG2 318/4885 |
| US-20100160248-A1 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS | GPX4, FABP6, CPT1A | SLC1A2 234/4885GSR 124/4885ARG2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.